Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma

doi:10.3748/wjg.v20.i1.235

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6030)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

299

WORD

200

HTML

3160

Figures (1-2)

171

Tables (1-4)

162

Sum=3992

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1051

Download

987

Sum=2038

Jan 7, 2014 (publication date) through Aug 24, 2024

Times Cited of This Article

Times Cited (24)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jan 7, 2014; 20(1): 235-241
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.235

Table 2 Clinical outcomes

Response	n(%)
PR	4 (12.9)
SD	10 (32.3)
Disease control (PR + SD)	14 (45.2)
Progressive disease	17 (54.8)
Survival outcome	median (range)
Median TTP	2.7 mo (1.0-14.8)
Median OS	7.8 mo (2.2-40.2)

PR: Partial response, 30% or more decrease in the sum of diameters of target lesions; SD: Stable disease, neither sufficient shrinkage to qualify as PR nor sufficient to qualify as disease progression; TTP: Time to progression; OS: Overall survival; PD: Progressive disease.

Citation: Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol 2014; 20(1): 235-241
URL: https://www.wjgnet.com/1007-9327/full/v20/i1/235.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i1.235